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Abstract
Background: Monoclonal antibodies and antibody fragments are powerful biotherapeutics for various debilitating diseases.
However, high production costs, functional limitations such as inadequate pharmacokinetics and tissue accessibility are the
current principal disadvantages for broadening their use in clinic.
Methodology and Principal Findings: We report a novel method for the long-term delivery of antibody fragments. We
designed an allogenous immunoisolated implant consisting of polymer encapsulated myoblasts engineered to chronically
release scFv antibodies targeted against the N-terminus of the Ab peptide. Following a 6-month intracerebral therapy we
observed a significant reduction of the production and aggregation of the Ab peptide in the APP23 transgenic mouse
model of Alzheimer’s disease. In addition, functional assessment showed prevention of behavioral deficits related to anxiety
and memory traits.
Conclusions and Significance: The chronic local release of antibodies using immunoisolated polymer cell implants
represents an alternative passive vaccination strategy in Alzheimer’s disease. This novel technique could potentially benefit
other diseases presently treated by local and systemic antibody administration.
Citation: Marroquin Belaunzaran O, Cordero MI, Setola V, Bianchi S, Galli C, et al. (2011) Chronic Delivery of Antibody Fragments Using Immunoisolated Cell
Implants as a Passive Vaccination Tool. PLoS ONE 6(4): e18268. doi:10.1371/journal.pone.0018268
Editor: Anil Kumar Tyagi, University of Delhi, India
Received September 19, 2010; Accepted February 25, 2011; Published April 20, 2011
Copyright:  2011 Marroquin Belaunzaran et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which
permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by the Swiss National Science Foundation, Consejo Nacional de Ciencia y Tecnologia of Mexico, the Foundation for Research
on Neurodegenerative Diseases, the Fondazione San Salvatore, the Swiss National Center of Competence in Research on Neural Plasticity and Repair, the Swiss
National Science Foundation, and ONELIFE Advisors SA. The funders had no role in the study design, data collection and analysis, decision to publish, or
preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: patrick.aebischer@epfl.ch
Introduction
Therapeutic monoclonal antibodies (mAbs) with more than 20
products in clinical use and over 200 candidates in clinical
investigation constitute a promising avenue for the treatment of
several major diseases including autoimmune, cardiovascular,
infectious diseases, cancer and inflammation [1,2,3]. Furthermore,
development of novel antibody targets for the treatment of several
neurological diseases such as Alzheimer’s disease (AD) is being
currently investigated [4,5,6,7,8]. However, major drawbacks that
presently limit the use of therapeutic antibodies following systemic
delivery is related to the poor distribution at the targeted tissues,
inadequate pharmacokinetics, and elevated costs of manufacture
[9,10].
The development of new methods for the continuous delivery of
antibodies and/or its fragments that would allow reduction of
interventions, prolonged retention at the targeted site, slow
clearance and low cost of goods is therefore highly desirable.
In the present work, we propose a novel way to potentially
release mAbs or antibody fragments in targeted tissues for
extended periods of time using semipermeable polymeric cell
implants. Surrounding genetically engineered cells producing
mAbs and/or antibody fragments with a synthetic permselective
membrane minimizes immunological responses by avoiding cell-
to-cell contact between the host tissue and the encapsulated cells,
while its design and porosity allows the inward diffusion of
nutrients, oxygen and the outward diffusion of antibodies into the
implanted tissue.
We show the feasibility of using an immunoisolated polymer
implant loaded with genetically engineered C2C12 mouse
myoblasts cells, to secrete single-chain fragment variable (scFv)
antibodies. As proof-of-concept, we tested this technology as an
immunotherapeutical approach for the treatment of AD using a
transgenic mouse model of the disease. Implants releasing scFv
antibodies placed in the brain parenchyma of APP23 transgenic
mice proved to be capable of continuously process, express and
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secrete the scFvb1 [11] antibody fragment targeted against the
EFRH epitope of the Ab peptide, the characteristic hallmark of
AD brain pathology [12]. In situ chronic expression of scFvb1
following a six-month immunotherapy in 14-months old APP23
mice reduced the accumulation and production of Ab as analyzed
with histological and biochemical markers. Functional assessment
in mice showed significant behavioral recovery of anxiety and
memory traits.
These results show that this novel technique to deliver
antibodies into targeted tissues can serve as an alternative
approach for the treatment of AD and potentially other major
diseases treated by passive vaccination strategies.
Results
Reduction of Ab in vitro following cell exposure to single
chain and monoclonal antibodies against human APP
scFvb1 is a single chain antibody recognizing the EFRH
tetrapeptide adjacent to the beta secretase cleavage site of human
amyloid precursor protein (APP) [11]. We previously showed that
intracellular expression of scFvb1 resulted in association with
newly synthesized APP in the endoplasmic reticulum. Formation
of this complex shielded the beta secretase cleavage site of APP
thus substantially reducing Ab production [11]. Here we
compared consequences on APP processing of extracellular
administration of scFvb1 or of the template b1 monoclonal
antibody [13] to cultured CHO cells expressing the Swedish
variant of human APP. When added to the culture medium the
27 kDa recombinant scFvb1 bound to surface exposed APP and
reduced the shedding of the APP ectodomain by 40% in a dose-
dependent manner (Figure 1A, E). The a-secretase cleavage was
poorly affected upon cell incubation with scFvb1 (,10% of
reduction, Figure 1B, E), while the b-secretase cleavage by
BACE1 (b-site APP cleaving enzyme) was reduced by 50%
compared to mock-treated cells (Figure 1C, E). Altogether,
exposure to scFvb1 substantially reduced intracellular production
and accumulation of Ab (Figure 1D–G).
Addition of the b1 monoclonal to the cell culture medium
weakly affected shedding of the APP ectodomain (approximately
10% reduction, Figure 1A, E). This is consistent with an
impaired access of the bulky, ,180 kDa full-length antibody
molecule to the EFRH epitope located close to the transmembrane
domain of APP. Reduction of total Ab (Figure 1D, E) and the
fraction of Ab trapped intracellularly (Figure 1F) was also
significantly smaller compared to cells exposed to the scFvb1. As
control treatment we used DAPT, a potent inhibitor of c-secretase
[14] that abolishes the generation of Ab (Figure 1D–G).
Despite the different capacity to actively interfere with Ab
production, both the single chain and the monoclonal antibodies
efficiently buffered the Ab released by cells in the culture medium.
In fact, no free Ab was detected in the supernatant after exposure
to scFvb1 or to b1, with all secreted Ab being associated with the
antibodies (Figure 1G). These data show that in situ delivery of
scFvb1 represents a powerful strategy with potential for beneficial
interference with Ab generation and for buffering neurotoxic Ab
forms.
Design of a polymeric cell implant
Next, we designed a device for in situ delivery of scFvb1 in the
mouse brain. To this end, we made use of polysulfone hollow fiber
membranes with an inner diameter of 280 mm, outer diameter of
360 mm and a length of 4 mm (Figure 2A) to be loaded with
C2C12 mouse myoblast cells engineered and selected for
continuous secretion of scFvb1 antibody fragments. We used a
fiber membrane with a molecular weight cut-off of ,100 kDa,
allowing the diffusion of the,27 kDa scFvb1 fragments. Scanning
electron microscopy was performed to assess the homogeneous
surface structure and porosity of the hollow fiber membrane
(Figure 2B, C). The hollow fiber capsules loaded with the
selected C2C12-scFvb1 cells were implanted in the posterio-
parietal cortex of APP23 mice (Figure 2D), a mouse-model of
AD-like pathology created by overexpressing human APP with the
Swedish mutation [15]. Localization of the polymeric cell implants
in the brain cortex of APP23-scFvb1 and APP23-mock mice was
visualized from coronal in vivo images using an MRI system
interfaced to a 14.1 Tesla magnet (Figure 2E). Four weeks
following the implantation, the local tissue distribution of the
scFvb1 was determined after an anti-histidine tag immunohisto-
chemical detection in paraformaldehyde-fixed brain sections of
APP23-scFvb1 mice (Figure 2F). scFvb1 staining was detected
over a maximal distance of 2 mm around the implantation site.
Encapsulation of genetically modified C2C12-scFvb1 cells
for scFvb1 secretion
Amongst the different C2C12-scFvb1 clones obtained after
transfection, one clone was selected according to the highest
scFvb1 secretion level and cell survival inside the polymer implant.
Indeed, in vitro evaluation of clone #24 showed that C2C12-
scFvb1 cells were secreting 31.160.6 ng of scFvb1 per 50’000 cells
per 24 hours (n = 4). Once encapsulated and kept in vitro for 3
months, polymeric cell implants were still producing 17 ng/24 hrs
of scFvb1. Cell survival within the device was investigated in vivo at
3 and 6 months post-implantation, showing evenly distributed
C2C12 cells intermingled with the polyvinyl alcohol (PVA) matrix
(Figure S1). The small decrease in the secretion of the capsule 6
months post-implantation may be due a small decrease of
surviving cells as well as a decrease of secretion by the C2C12
cells that have differentiated in myotubes.
scFvb1-treated APP23 mice display reduced anxiety-like
behavior in the light and dark and elevated zero maze
test, and improved working memory in the Morris water
maze
C2C12-scFvb1 capsules were implanted bilaterally in the
posterio-parietal cortex, and animals were evaluated behaviorally
(Figure 3A) in two different anxiety-like tests, light and dark (L&D)
and elevated zero maze (EZM) (Figure 3B, C) and in the Morris
water maze (MWM) for cognitive functions (Figure 3D–F).
In the L&D test, the distance traveled in the open lighted and
anxiogenic compartment indicated anxiety-like behavior. Signifi-
cant differences were observed between the APP23-scFvb1 and
WT-littermates groups in the total distance traveled in the light
compartment compared to the APP23 group (p,0.05)
(Figure 3B). Similarly, APP23-scFvb1 and WT-littermates
animals showed a significant difference in the distance covered
in the light compartment (without the transition zone) compared
to both APP23 and APP23-mock groups (p,0.05) (Figure 3B),
indicating enhanced anxiety-like behavior in the non-scFvb1
treated APP23 mutants. No differences between groups were
found in distance moved in the transition zone, indicating a lack of
changes in general exploratory behavior (Figure 3B).
In the EZM test, APP23 and APP23-mock mice moved less in the
maze than WT mice, due to a specific reduction in both total
movement in the arena (p,0.05), and in the open arms (p,0.01)
(Figure 3C), indicating enhanced anxiety-like behavior in the non-
scFvb1 treated APP23 mutants. APP23-scFvb1 mice differed from
the untreated and mock mutants, but not from WT controls in their
Delivery of Antibody Fragments Using Cell Implants
PLoS ONE | www.plosone.org 2 April 2011 | Volume 6 | Issue 4 | e18268
total movement in the arena (p,0.05), and in the open arms
(p,0.001) (Figure 3C), indicating reduced anxiety-like behavior.
We next examined the impact of scFvb1 treatment on cognitive
functions, as evaluated 5.5 months after treatment on spatial learning
and working memory functions in the MWM. No significant
differences were found between WT-littermates and all APP23
groups in their distance moved to find the hidden platform over the
three spatial learning sessions (days 1–3) (Figure 3D), and did not
differ from each other in their daily average distance to reach the
platform (Figure 3E). Following the reversal learning (day 4), the
APP23-scFvb1 and WT-littermates showed a trend to reach the
platform in shorter distance compared with both control APP23
groups (p,0.1) (Figure 3D, E). No locomotor or visual deficits were
observed between groups on the visual platform task (day 8).
Animals were then challenged to the delayed-matching-to-place
(DMTP) [16] trials (days 11 and 12). On the first day no difference
in performance was observed between the different groups
(Figure 3D, E). However on the second day of the DMTP trials,
APP23 and APP23-mock mice showed impaired performance with
regards to both WT (p,0.05) and APP23-scFvb1 (p,0.01) mice
(Figure 3D, E). Therefore, scFvb1 treatment improved mice
working memory to re-locate the platform in the novel position as
indicated by their shorter average escape distances (Figure 3E).
To further assess the effectiveness of the treatment in learning
acquisition, we analyzed a compound measure of mice’s behavior
by collapsing data corresponding to the second trials for each of
the cognitive challenges given in the MWM (i.e., days 1, 4, 11 and
12). As shown in Figure 3F, this analysis indicated that WT and
APP23-scFvb1 mice performed better in their learning strategy
than the APP23 and APP23-mock mice (p,0.05).
scFvb1 secretion in the brain parenchyma of APP23 mice
and scFvb1 capsule release
Mice were sacrificed and the polymeric cell implants were
retrieved six months post-implantation for evaluation of scFvb1
secretion. The retrieved devices released 1061.5 ng of scFvb1/24 h
compared to the 2164 ng of scFvb1/24 h at the time of
implantation, confirming the sustained release of scFvb1 fragments
throughout the implantation period (Figure 4A). Histological
analysis of the capsules confirmed the survival of the cells 6 months
following implantation (Figure 4B). Anti-histidine tag immunohis-
tochemical detection of scFvb1 fragments showed the presence of the
scFvb1 surrounding the implantation site, covering the cortex
(posterio-parietal region), the hippocampus (dorsal region at the
CA1, CA2, CA3, CA4, and dentate gyrus) (Figure 4C) and, to a
lesser extent, other areas near the implants and ventricles. No scFvb1
was detected in the APP23 and APP23-mock brains (Figure 4C).
Total amyloid beta is reduced after scFvb1 delivery from
encapsulated cells
The total Ab load was ascertained six months post-scFvb1
treatment using immunohistochemical and congophilic stainings.
In 14-month-old APP23 mice, Ab plaque deposition was
regionally distributed throughout the olfactory bulb, the cortex
(although more densely concentrated in the ‘parietal’ and
‘occipital’ regions) and, to a lesser extent in the hippocampus.
Figure 1. scFvb1 decreases the accumulation and production of Ab and sAPPb by interfering with the BACE1 cleavage of huAPP. (A–
E) Immunoprecipitations from cell protein extracts reveal that scFvb1 added extracellularly to CHO mutant huAPP cells reduces the amount of
soluble amyloid precursor protein beta (sAPPb) by specifically interfering with the BACE1 cleavage site (C, E), thus decreasing the production of Ab
(D, E), and of the total soluble amyloid precursor protein (sAPP) (A, E). (A–E) The addition of b1 monoclonal antibody does not interfere with the
BACE1 cleavage site of sAPPb (A–E). (A–E) DAPT as positive control treatment abolishes the total production of Ab by inhibiting the c-secretase
activity, favoring the alpha cleavage of APP. (E) All densitometry values of immunoprecipitations are plotted as the % change against mock cells. (F)
Intracellular accumulation and production of Ab is considerably reduced only in the presence of scFvb1. (G) Ab released from the cells in the culture
medium was completely bound to either b1 or scFvb1 antibody molecules.
doi:10.1371/journal.pone.0018268.g001
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Congo red staining revealed that the size of Ab insoluble plaques
(Figure 5A) was significantly reduced in the brain slices of APP23-
scFvb1 animals with regards to both APP23 (p,0.05) and APP23-
mock (p,0.01) (Figure 5B), and with a marked clearance in the
hippocampus and posterio-parietal cortex regions as compared to
APP23 and APP23-mock (p,0.001) (Figure 5C).
ELISA from brain homogenates revealed that the soluble Ab
levels were significantly lower in APP23-scFvb1 in the posterio-
parietal cortex and hippocampus as compared to APP23 (p,0.05)
(Figure 6A), and a trend was observed with APP23-mock (p,0.1).
The insoluble levels of Ab were significantly reduced in scFvb1
antibody treated animals in the posterio-parietal cortex and
hippocampus (p,0.05) (Figure 6B), confirming the observations
from the congophilic quantification.
Microhemorrhages and cerebral amyloid angiopathy were
scarce in all groups (data not shown). No differences between
treated and non-treated animals were observed.
The b-site cleavage of huAPP is affected in scFvb1
treated animals
Western blot analysis from the brain homogenates showed an
overall 80% reduction of the soluble APPb in the posterio-parietal
cortex of APP23-scFvb1 animals (p,0.001) (Figure 6C). The b-
secretase cleavage was less affected in the hippocampus accounting
for only a 30% reduction of sAPPb (p,0.2) (Figure 6D),
suggesting that the majority of the antibody diffused in the cortical
region where the capsule was implanted. The product of a-
secretase cleavage sAPPa and the amount of full length human
APP (FL huAPP) were not significantly affected by the expression
of scFvb1 (Figure 6C, D).
Discussion
Currently one of the principal challenges for the clinical use
of antibody fragments is to modify the pharmacokinetic
properties to achieve a balance of prolonged retention at the
target site and fast systemic clearance. Modifications of scFv’s
such as PEGylation are able to increase the half-lives up to 14-
fold in vivo [17], but significantly lower tissue penetration. Other
explored routes such as nasal administration of scFv’s are able to
increase their availability inside the brain [18]. However, the
approaches require continuous interventions to achieve thera-
peutic effects [9,10]. Here, we have show the feasibility of an
original way to continuously release scFv antibody fragments in
situ to enhance the availability and accumulation to the target
tissue.
Figure 2. Polysulfone (PS) hollow fiber capsule use in mouse brain implantation. (A) Macroscopical appearance of a PS hollow fiber
capsule used for the encapsulation of C2C12 cells. A 4 mm PS membrane glued and connected to a stainless steel tip facilitate the loading of cells,
and the plastic hub serves to plug in a Hamilton syringe containing the cells. (B) The membrane surface of the PS-membrane imaged with a SEM
microscope at610,000 reveals its porosity corresponding to a cut-off of ,100 kDa. Scale bar 2 mm. (C) The coronal section of the PS-membrane
imaged with a SEM microscope at61000 shows an even homogeneous wall structure. Scale bar 20 mm. (D) Sagittal schematic representation of the
implantation site in the posterio-parietal cortex of a mouse brain. (E) MRI coronal image from an APP23 mouse brain showing the placement of the
polymeric cell implants following bilateral implantation. (F) Immunohistochemical coronal sections of an APP23-scFvb1 mouse brain revealing the
extent of diffusion of scFvb1 around the site of implantation. Magnification 16, scale bar 1 mm.
doi:10.1371/journal.pone.0018268.g002
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Figure 3. Reduced anxiety-like behavior in APP23-scFvb1 as determined in the L&D and EZM tests, and improved working memory
performance in the Morris water maze (MWM) test. (A) Experimental design of the behavioral battery of tests performed in APP23, APP23-
mock, APP23-scFvb1 and control aged matched WT-littermates during the course of the therapy. (B) The L&D test shows that WT-littermates and
APP23-scFvb1 mice display reduced anxiety-like behavior for the distance traveled in the exposed and anxiogenic open light compartment [light
compartment total (F(3,22) = 3.2; p = 0.042), light compartment w/o the transition zone (F(3,22) = 3.4; p = 0.034), and transition zone (F(3,22) = 0.67, n.s.)],
Delivery of Antibody Fragments Using Cell Implants
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The use of single chain antibodies (scFv) for passive immuni-
zation constitutes an alternative strategy to immunotherapies
based on monoclonal antibodies [9,19,20,21]. The smaller size of
these molecules (approximately 27 kDa) improves tissue penetra-
tion [22], while the absence of the Fc portion may enhance the
blood-brain barrier infiltration and preclude activation of the
complement system and inflammatory reactions. Limitations for
their therapeutic use for systemic delivery are related to their
shorter half-life in the blood (2 h) compared to full antibodies (1–
2 w) [1,22]. The local delivery of antibody fragments presents a
clear advantage over applications when systemic delivery is not
safe, or not efficient due to poor bioavailability.
As shown in the in vitro studies, immunotherapy with scFvb1
could not only prevent deposition and oligomerization of Ab by
binding to the soluble form but also reduce its production by
binding membrane-exposed huAPP due to its increased capacity
to access the epitope. In vivo sustained release of scFvb1 fragments
from the polymeric cell implants considerably reduced the Ab1–42
burden in the brain of APP23 mice. Results indicated that
clearance of Ab by scFvb1 most likely implicates the interaction of
the antibody with monomeric and small oligomeric Ab assemblies,
either by forming a soluble-complex scFvb1/Ab that impedes
accumulation, and/or as a membrane-complex huAPP/scFvb1
that blocks the production of Ab. Presently, we cannot exclude
that alone the overexpression of human APP with the Swedish
mutation may account for the behavioral phenotype observed in
the APP23 mice, and that scFvb1 treatment neutralizes the
potential pathogenic effect of human mutant APP rather than of
Ab accumulating in the brain. On the other hand, in situ
production of scFvb1 was found to affect primarily the generation
of Ab by b-secretase as well as to interact with extracellular Ab,
where sAPPa and full-length APP were unchanged suggesting an
Ab-driven process. In addition, we discard that reduction of Ab
load occurs via microglial phagocytosis [19,21], given that the
scFvb1 fragment lacks the Fc-region of the parental b1 antibody
we argue in favor of a preventive mode of action where scFvb1
inhibits the initial accumulation of Ab species.
Behavioral evaluation during the course of the immunotherapy
showed that reduction of Ab levels after scFvb1 delivery modified
behavioral traits related to anxiety and working memory in the
APP23 mice. Ab progressive accumulation has been previously
reported to increase anxiety in numerous AD mouse models
[23,24] and to deteriorate cognitive-associated areas related to
spatial and working memory [25,26] and these findings were
confirmed in our study. They also showed improved learning
strategies during the second MWM learning trials, and displayed
improved working memory in the DMTP paradigm.
CAA frequency and severity was not affected by immunization.
Because robust CAA and microhemorrhages have only been
reported in .19 month-old APP23 mice [13,25,27], it is
conceivable that the lack of differences between the various
groups of animals is caused by the low presence of CAA at the
time of sacrifice [25,27].
In summary, we have established a novel in situ passive
immunotherapy strategy using an immunoisolated allogeneic
implant capable of expressing, processing, and secreting scFv
antibodies against the Ab peptide in the brain parenchyma of
APP23 AD transgenic mouse. We show that local and sustained
release of scFvb1 fragments from polymeric cell implants over a 6-
month treatment significantly reduce the Ab1–42 burden, and
modify behavioral traits related to anxiety and working memory.
The present data demonstrates the proof of principle of an
innovative technology for the sustained release of antibodies in vivo.
The use of polymeric cell implants is a promising alternative tool
to the current passive vaccination strategies. The potential
therapeutic advantages of this singular immunoisolated device
rely on its capacity to release for long-term antibodies and/or
antibody fragments, while its design allows retrieveabiity for either
replacement or interruption of the treatment [28,29,30]. This type
of technology has the possibility to be scaled-up by using enlarged
cell encapsulation devices to potentially achieve physiological
levels of antibodies for local and systemic applications. Indeed the
technique has been previously validated for the systemic delivery
of erythropoietin in mice [31], and for the local brain delivery of
neurotrophic factors in rodents [30], non-human primates [32],
and in two clinical trials [28,33]. Beyond its potential for the
treatment of AD, this technology could also benefit other major
diseases presently treated by antibody administration.
Materials and Methods
In vitro test of b1 and scFvb1 antibodies
CHO cells ectopically expressing the Swedish variant of human
APP were incubated in the presence of 1.88 mM of antigen-
binding site (scFvb1 or b1) [11,13], or in the presence of 500 nM
DAPT added to the cell culture media. Cells were metabolically
labeled for 3 h with 35S-methionine and -cysteine (0.05 mCi/dish;
Perkin Elmer). The labeled APP and APP fragments were
immunoisolated from cell culture media or from cell lysates with
appropriate antibodies and separated electrophoretically as
previously described [11].
Generation of a stable C2C12 cell line for encapsulation
C2C12 mouse myoblasts (ECACC) at 80% confluency were
transfected using Lipofectamine 2000 (Invitrogen) with 3 mg of a
ScaI-linearized pRK5 plasmid for expression of scFvb1-His6[11], as
control we used cells transfected with the pRK5 plasmid without
the transgene (mock). We used 1.5 mg of a PvuI-linearized
pCDNA3 plasmid for geneticin antibiotic selection of transfected
cells. Three positive stable clones that maintained high level of
expression of scFvb1 for several months in culture were selected
for their encapsulation into hollow fiber membranes.
Hollow fiber capsule design
Stainless steel tips (EFD) (OD: 230 mm; ID: 100 mm) were
detached from their hub and connected to the tip of 4 mm long
when compared to APP23 and APP23 mock animals. (C) The EZM test show that WT and APP23-scFvb1 mice display reduced anxiety-like behavior for
their total distance traveled in the arena (F(3,17) = 5.32; p = 0.009), and in the open arms (F(3,17) = 5.25; p = 0.007), when compared to APP23 and APP23-
mock animals. (D, E) The MWM test did not show significant effects during days 1-3 in the learning sessions (F(3,24) = 1.42, n.s.), a tendency towards
significance was observed in the reversal sessions (F(3,24) = 2.38, p = 0.09). In the delayed-matching-to-place (DMTP) task APP23-scFvb1 mice and WT-
littermates displayed improved working memory on day 12 when compared to APP23 and APP23-mock, no differences were observed in the DMTP
day 11 (F(3,24) = 0.92, n.s.). (F) APP23 and APP23-mock mice showed clear impairments in their learning acquisition, as indicated by their longer
distance to find the platform when the second trials for each cognitive challenge were collapsed, while APP23-scFvb1 mice showed an improved
working memory that did not differ from WT mice (F(3,24) = 6.01; p = 0.003). Results are expressed in centimeters (cm) for the distance. Error bars
indicate s.e.m. +p,0.1, *p,0.05 and **p,0.01 as determined by one-way ANOVA followed by the LSD post-hoc analysis.
doi:10.1371/journal.pone.0018268.g003
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Figure 4. scFvb1 release and survival of encapsulated C2C12 cells. (A) ELISA immunoassay reveals the amount of scFvb1 released by C2C12-
scFvb1 polymer capsules prior to implantation, and 6 months post-explantation. (B) Hematoxylin–eosin staining performed on the retrieved
polymeric cell implants pre- and post-implantation show the presence of numerous cells scattered within the PVA matrix. Magnification 46, scale bar
100 mm. (C) Immunohistochemical detection of scFvb1 using an anti-histidine tag antibody. Left, APP23 mouse brain without surgery. Middle, APP23
mouse that received bilateral implantation of polymer capsules with control C2C12-mock cells. Right, staining of APP23 mouse that received bilateral
implantation of polymer capsules with C2C12 cells expressing the recombinant scFvb1 antibody fragment, revealing the diffusion around the site of
implantation. Magnification 16, scale bar 1 mm.
doi:10.1371/journal.pone.0018268.g004
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polysulfone (PS) hollow fiber semipermeable membranes (Min-
ntec) (OD: 360 mm; ID: 280 mm; molecular weight cutoff:
100 kDa) using a photo-polymerized acrylic-based glue (Ablestic
Laboratories). Hollow fiber membranes were filled with a
polyvinyl alcohol (PVA) sponge (Rippey Corporation) used for
cell anchorage and were obtained using a hollow drill with an
internal diameter corresponding to the inner dimensions of the
capsule. The PVA rods were sonicated in ultra pure water and
dried. The matrices were inserted into the 4 mm long semi-
permeable PS hollow fibers and sealed. Capsules were sterilized
with ethylene oxide and kept 10 days at room temperature to
eliminate traces of gas.
SEM imaging
PS hollow fiber membranes structure was visualized using a
Philips XLF30 field emission gun scanning electron microscope
(FEG SEM), equipped with an Everhart-Thornley secondary-
electron (SE). Membranes were dehydrated in alcohol baths from
70 to 100% followed by a 400 A˚ gold plasma coating for
visualization at different resolutions.
Cell loading
C2C12-scFvb1 clones (#9, 15, and 24) were harvested using
0.125% trypsin-EDTA and diluted with 50% DMEM 5% FBS
+50% HBSS to achieve a suspension of 50,000 cells/ml culture
medium. Using a 50-ml syringe (Hamilton) fitted with an adaptor
hub, 1 ml of cell suspension was injected into the capsule. The hubs
and steel tip were removed and the extremity of the capsules
sealed. The capsules were washed in HBSS 1% FBS for 1 hour
and then transferred to DMEM, 10% FBS (5% CO2, 37uC) for 21
days before implantation into the brain cortex of mice.
scFvb1 detection
PVC plates were coated with Ab1–40 (10 ng/mL). scFvb1
standards were concentrated from culture medium using his-tag
columns (GE healthcare) and purified using fast protein liquid
chromatography. As primary antibody we used culture media
supernatant of capsules expressing the scFvb1. As a secondary
antibody we used anti-his tag biotinilated (Serotec) and the
substrate solutions according to the manufacturer (R&D systems).
To detect the presence of metabolically active C2C12-mock cells
inside capsules, a lactate assay kit was used (BioVision) (data not
shown).
Animal Care and Treatment
Ethic statements: All animal experiments were approved by the
SCAV (Service de la consommation et des affaires veterinaires) in
the Canton de Vaud, and carried out in accordance with the
European Community Council Directive (86/609/EEC) for care
and use of laboratory animals. Permit number: 1935.
Figure 5. scFvb1 decreases the accumulation Ab in vivo. (A) Representative congophilic stained sections of Ab plaques from brains of APP23,
APP23-mock and APP23-scFvb1 reveal the reduction of the amyloid plaque number following therapy with C2C12-scFvb1 polymer implants.
Magnification 26, scale bar 500 mm. (B) Percentage of positive congophilic plaque stainings from entire brain sections is reduced in APP23-scFvb1
mice. (C) Percentage of positive congophilic plaque stainings in the hippocampus and posterio-parietal cortex region is reduced on the region were
the antibody diffuses from the C2C12-scFvb1 polymer implants.
doi:10.1371/journal.pone.0018268.g005
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Subjects were heterozygous females APP23 mice and their non-
transgenic WT-littermates generated as previously described [15].
These mice express human APP751 cDNA with the Swedish
double mutation under control of the neuron-specific mouse Thy-
1 promoter fragment. They produce a seven-fold excess of huAPP
compared to the endogenous murine APP.
Eight-month age matched female APP23 mice were housed in
12 h light/dark cycle, with ad libitum access to food and water.
Deeply anesthetized animals were placed into the stereotaxic
frame (Kopf Instruments) equipped with a precise micromanipu-
lator with a horizontal arm in a 79u angle. Four-millimeter long
capsules were bilaterally implanted in the cortex (anterior-
posterior: 21.1 mm, lateral: 61.2 mm, ventral: 25.5 mm, tooth
bar: 27 mm, according to the atlas of Paxinos and Franklin [34])
of 16 female APP23 mice. The first group consisted in 9 APP23
mice implanted with C2C12-mock, and the second with 7 APP23
mice implanted with C2C12-scFvb1 capsules.
Capsule histology
Following the ELISA-scFvb1 immunoassay, capsules retrieved
from the animals were fixed overnight in 10% formalin and 1%
picric acid and dehydrated under an alcohol cycle in preparation
for glycol–methacrylate embedding (Leica Instruments). The
capsules were cut at 9 mm-thickness using a LEICA microtome
Figure 6. scFvb1 decreases the production of Ab and sAPPb by interfering with the BACE1 cleavage of huAPP in vivo. (A, B) Ab1–42
ELISA from brain protein extracts from soluble and insoluble fractions. (A) Ab levels from the TBS soluble fractions are significantly reduced in the
posterio-parietal cortex and hippocampus in APP23-scFvb1 mice when compared to APP23 mice. (B) Ab levels of the Triton-X100 insoluble fraction
are significantly reduced in the posterio-parietal cortex and hippocampus region of APP23-scFvb1 treated mice when compared to both APP23 and
APP23-mock. (C, D) Western blot analysis measured by the protein/GAPDH ratio are analyzed and plotted as the % change against APP23 protein
levels. Full length APP, and the soluble amyloid protein precursor alpha (sAPPa) display no significant changes, while soluble amyloid precursor
protein beta (sAPPb) is considerably reduced after exposure to scFvb1 in vivo in the posterio-parietal cortex. Representative immunoblots are
depicted below the graphs (C, D). Error bars indicate s.e.m. *p,0.05, **p ,0.01 and ***p,0.001 as determined by one-way ANOVA followed by LSD
post-hoc analysis.
doi:10.1371/journal.pone.0018268.g006
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equipped with glass knifes and stained with hematoxylin–eosin
(HE).
Behavioral analysis
Behavioral testing was performed in female APP23 mice (n = 21)
and their WT-littermates (n = 7) during the light cycle period (8
am to 2 pm). In all tests, mice trajectories were recorded with a
vertically mounted camera and analyzed with a video tracking
software (Ethovision 3.1.16, Noldus). In order to maximize
homogeneity of groups before scFvb1 capsule implantation, 7
month-old APP23 mice (n= 21) were tested for anxiety-like,
locomotor and exploration behaviors in the elevated plus maze
(EPM), the open field and the novel object (OF/NO) reactivity test
(Methods S1) and subsequently we matched them so that not
significant differences were observed between the subgroups
(APP23 n= 5, APP23-mock n= 9, APP23-scFvb1 n= 7) (Table
S1).
To evaluate the behavioral impact of the scFvb1 treatment,
three tests were administered at different time points after capsule
implantation (Figure 3A). (a) Light Dark test (L&D) (Methods S1);
(b) Elevated zero maze test (EZM) (Methods S1); and (c) Morris water
maze (MWM) (Methods S1).
Magnetic resonance imaging (MRI)
Five APP23-mock, and 5 APP23-scFvb1 mice were anesthetized
using 1.360.2% of isoflurane in oxygen using a nose mask. Body
temperature was kept at 3760.5uC. Images were acquired on an
MRI System (Varian) interfaced to a 14.1 Tesla magnet with a 26-
cm horizontal bore (Magnex Scientific). A home-built quadrature
surface coil consisting of two geometrically decoupled 14-mm-
diameter single loops was used as a transceiver. Localizer images
were obtained in the coronal plane using a multislice fast spin echo
protocol with an echo time of 60 ms, a repetition times of
5000 ms, a slice thickness of 0.6 mm and an isotropic in-plane
resolution of 78 mm.
Analysis of brain samples
Mice were deeply anesthetized by an overdose of pentobarbital
and transcardially perfused with ice-cold PBS. The brain was
recovered and capsules were removed and placed in DMEM 10%
FBS at 37uC, 5% CO2. Brains were sagittally sectioned in two; the
hippocampus and cortex of the left hemisphere were immediately
dissected for protein extraction, and the right hemisphere was
immediately fixed in 4% paraformaldehyde (Fluka-Sigma) for
2 hours and then transferred into 25% sucrose in PBS and placed
at 4uC overnight. Twenty-five mm thick coronal sections were
harvested on a freezing stage sliding microtome (Leica SM2400).
Immunohistochemistry
For immunofluorescence studies, slices were tested with the
following primary antibodies: anti-amyloid beta 4G8 (Acris),
mouse anti-glial fibrillary acidic protein (Novus Biologicals), and
anti-Iba1 (Osaka, Japan). As secondary antibodies we used 488-
and/or 568-Alexa fluor dyes (Molecular Probes). For detection of
the scFvb1, an anti-histidine tag mouse monoclonal antibody
(Serotec) was used, followed by peroxidase treatment M.O.M
(Vector Laboratories), and revealed with the 3,39-diaminobenzi-
dine (DAB) (Pierce). We performed congo red histology as
previously described [35,36] on ten coronal brain sections
(100 mm apart; every 4th sections) taken from each animal in the
region where the capsule was placed. Entire brain slices were
captured in the bright field with a motorized stage on the Leica
DM5500 microscope (software: Leica LAS) at a 106 resolution.
Each brain slice was segmented from the background to obtain the
brain surface followed by the quantification of the size of the
amyloid plaques. Both processes were performed through different
channel manipulation of the RGB images and then by object
detection. Artifacts were avoided by filtration on shape and size.
The semi-automated journals were performed with META-
MORPH 7.5 (Universal-Imaging). Cerebral amyloid angiopathy
and microhemorrhages were quantified using a double staining
with 4G8 antibody in DAB (described above), and counterstained
with the Prussian blue method for hemosiderin-positive microglial
cells in eight coronal brain sections (150 mm apart) throughout the
sector where the capsule were implanted.
Protein extraction analysis
We performed soluble (Tris-buffered saline (TBS)), detergent-
soluble (TBS with 1% Triton X-100) and insoluble (5 M GuHCl)
extracts as previously described [37]. Fractions were analyzed for
the quantification of human Ab1–42 using a colorimetric sandwich
ELISA kit (Biosource). Western blot analysis from protein extracts
were separated using sodium dodecyl sulfate polyacrylamide
elecrophoresis and transferred onto nitrocellulose membranes,
where they were probed with the primary mouse monoclonal
CT55 (Sigma) antibody against the C-terminal APP; the mouse
anti-Ab 6E10 (Signet) for sAPPa; and the mouse monoclonal 6A1
(IBL) for sAPPb-Swedish. Primary antibodies were detected with
Alexa Fluor 680 anti-goat or anti-rabbit antibodies (Invitrogen-
Molecular Probes) using an Odyssey Infrared Imaging System (LI-
COR Biosciences). Densitometry analysis was performed using the
Odyssey application software (Version 2.1) (LI-COR Biosciences)
and normalized with the housekeeping protein glyceraldehyde 3-
phosphate dehydrogenase (GAPDH) (Abcam) using an anti-mouse
Alexa Fluor 800 antibody.
Statistics
Pre-implantation and post-implantation behavioral data were
analyzed using a one-way analysis of variance (ANOVA) followed
by an LSD post-hoc test, where appropriate. Water maze data
were analyzed using ANOVA for repeated measures for general
performance across spatial learning in trials; one-way ANOVAs
were applied on block data for each testing day followed by a post-
hoc LSD test. Significance of results was accepted at p#0.05. Data
are expressed as means 6 S.E.M.
Supporting Information
Figure S1 Hematoxilin-eosin (HE) staining performed
on retrieved capsules recovered from in vivo intracra-
nial implantations in C57BL/6 mice. (A, B) HE staining of
capsules retrieved 3 months post-implantation showing the
presence of numerous scattered cells within the PVA matrix. (C,
D) HE staining of capsules retrieved 6 months post-implantation
showing the presence of numerous scattered cells within the PVA
matrix. Magnification 106, scale bar 100 mm.
(TIF)
Table S1 Distribution of three different groups of
APP23 mice following behavioral screenings. Seven
month-old female APP23 mice (n = 21) were subjected to
behavioral tests in the elevated plus maze test, the open field test
and the novel object test before capsule implantation. Mice were
matched and homogeneously distributed according to their body
weight, behavioral traits of anxiety, locomotion and exploration.
Analysis of variance confirmed that significant differences did not
exist between the subgroups (APP23, APP23-mock & APP23-
scFvb1). Results were analyzed using a one-way analysis of
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variance (ANOVA), significance of results was accepted at
p#0.05.
(DOCX)
Methods S1 Behavioral tests.
(DOCX)
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